<code id='14278B0446'></code><style id='14278B0446'></style>
    • <acronym id='14278B0446'></acronym>
      <center id='14278B0446'><center id='14278B0446'><tfoot id='14278B0446'></tfoot></center><abbr id='14278B0446'><dir id='14278B0446'><tfoot id='14278B0446'></tfoot><noframes id='14278B0446'>

    • <optgroup id='14278B0446'><strike id='14278B0446'><sup id='14278B0446'></sup></strike><code id='14278B0446'></code></optgroup>
        1. <b id='14278B0446'><label id='14278B0446'><select id='14278B0446'><dt id='14278B0446'><span id='14278B0446'></span></dt></select></label></b><u id='14278B0446'></u>
          <i id='14278B0446'><strike id='14278B0446'><tt id='14278B0446'><pre id='14278B0446'></pre></tt></strike></i>

          
          WSS

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion